Impact Factor: 9.9 ISSN-L: 2544-980X

Viral Hepatitis B+D: Modern Course

Vafakulov S. H. [1], *Jumanazarov Sardorbek* [2], *Khidirov Akbar* [3], *Bekmirzaev Sanjar* [4], *Kuziyeva Dilobar* [5]

Abstract: Hepatitis B (HBV) and Hepatitis D (HDV) coinfection significantly worsens liver disease outcomes, leading to higher risks of cirrhosis and liver cancer. This article reviews the modern understanding of HBV+HDV coinfection, covering its pathogenesis, diagnosis, and treatment. Current therapies, including interferon and emerging antivirals like bulevirtide, are discussed, along with the importance of HBV vaccination for prevention. The need for more effective treatments and global public health efforts to reduce coinfection rates is emphasized.

Keywords: Hepatitis B, Hepatitis D, Coinfection, Antiviral therapy, Liver cirrhosis, Pathogenesis, Diagnosis, Bulevirtide, Vaccination, Hepatocellular carcinoma.

Introduction

Hepatitis B virus (HBV) and Hepatitis D virus (HDV) coinfection is a serious global health concern, affecting millions of individuals worldwide. HBV alone is one of the leading causes of chronic liver disease, but when coinfected with HDV, the clinical outcomes become significantly worse. HDV is a defective virus that depends on HBV for replication, and this dual infection leads to more rapid disease progression, including higher rates of liver cirrhosis, liver failure, and hepatocellular carcinoma compared to HBV monoinfection. Although advancements in antiviral treatments for HBV have been made, managing HBV and HDV coinfection remains challenging due to the lack of effective and widely available treatment options. This article aims to provide a comprehensive overview of the modern course of HBV+HDV coinfection, exploring recent advancements in the understanding of its pathogenesis, diagnostic methods, and treatment strategies. Additionally, the importance of vaccination and public health efforts in preventing the spread of HBV and indirectly reducing HDV infections will be discussed.

Materials and Methods

This section provides an overview of the approaches used to study the clinical course, diagnosis, and treatment of Hepatitis B (HBV) and Hepatitis D (HDV) coinfection. The analysis incorporates a systematic review of current literature, clinical trials, and expert guidelines on HBV+HDV coinfection, focusing on pathogenesis, diagnostic methods, and treatment outcomes.

Study Design: A literature review was conducted by analyzing peer-reviewed articles published between 2010 and 2024. Studies were selected from databases such as PubMed, Scopus, and Google Scholar. Criteria for inclusion were clinical studies, randomized controlled trials (RCTs), and meta-analyses focusing on HBV and HDV coinfection, diagnosis, and treatment.

Patient Data and Diagnostic Criteria: Patient data from relevant studies were analyzed to understand the course of HBV+HDV coinfection. Key diagnostic tools examined include:

- Serological tests: HBsAg (Hepatitis B surface antigen), Anti-HDV antibodies, HDV RNA, and HBV DNA quantification.

[1] Doctor of Medical Sciences, Professor, Samarkand State Medical University, Department of Infectious Diseases
[2,3,4,5] Samarkand State Medical University, 2nd-year Residents of the Department of Infectious Diseases

- Liver function tests: Including ALT (alanine aminotransferase) and AST (aspartate aminotransferase) to evaluate liver damage.
- Imaging techniques: Ultrasound and elastography to assess liver fibrosis and cirrhosis.

Treatment Methods: The review of treatment strategies includes:

- Nucleos(t)ide analogs (for HBV suppression).
- Pegylated interferon-alpha (for managing HBV and HDV coinfection).
- Emerging therapies: Focus on bulevirtide, a recent antiviral developed specifically for HDV.
- Outcomes from liver transplant studies in patients with advanced liver disease due to HBV+HDV coinfection were also considered.

Statistical Analysis: Data from clinical studies were aggregated to analyze the efficacy of various treatments in reducing viral load, improving liver function, and preventing the progression of cirrhosis. Success rates of therapies were compared using statistical significance tests where applicable, including p-values and confidence intervals to assess treatment impact.

This methodology provides a robust foundation for understanding the modern clinical management of HBV and HDV coinfection.

Results and Discussion

Results:

Prevalence of HBV+HDV Coinfection: The reviewed studies indicate that HBV and HDV coinfection remains a significant global health issue, with higher prevalence in regions like Africa, the Middle East, and parts of Eastern Europe. Up to 5% of HBV-infected individuals are estimated to be coinfected with HDV, contributing to an increased burden of liver-related complications.

Disease Progression: Compared to HBV monoinfection, patients with HBV+HDV coinfection show a markedly accelerated progression to cirrhosis and hepatocellular carcinoma (HCC). Studies demonstrate that up to 70% of coinfected patients develop cirrhosis within 5 to 10 years, compared to 10-30% of those with only HBV. Additionally, HDV-infected patients are at a significantly higher risk of developing HCC, even in the absence of cirrhosis.

Diagnostic Efficacy: Diagnostic markers such as HBsAg, Anti-HDV antibodies, HDV RNA, and HBV DNA quantification have proven effective in identifying HBV+HDV coinfection. HDV RNA quantification was shown to be the most reliable marker for assessing active HDV infection. Liver function tests and imaging techniques (ultrasound and elastography) were useful in evaluating liver damage and fibrosis.

Treatment Outcomes: Pegylated Interferon-alpha: In several trials, pegylated interferon-alpha showed limited efficacy, with sustained virological response (SVR) rates ranging from 20-30%. The majority of patients experienced a relapse of HDV viremia after discontinuing treatment.

- Nucleos(t)ide Analogs: Though effective in controlling HBV replication, these drugs had little impact on HDV replication, indicating the need for HDV-specific therapies.
- Bulevirtide: Recent studies of bulevirtide, an entry inhibitor targeting HDV, have shown promising results. Patients treated with bulevirtide demonstrated significant reductions in HDV RNA levels and improved liver function, with a 50-60% virological response rate in early trials. Bulevirtide has become a key focus for future HBV+HDV therapy.

Discussion:

The clinical course of HBV+HDV coinfection is significantly more severe than HBV monoinfection, underscoring the need for improved diagnostic and treatment approaches. HDV's dependence on HBV for replication makes coinfection particularly challenging to manage. Despite advancements in

antiviral therapies for HBV, treatment options for HDV remain limited, with interferon therapy offering modest success and high relapse rates.

The emergence of bulevirtide as a targeted therapy for HDV represents a significant step forward, with clinical trials showing promising efficacy in reducing viral load and improving liver function. However, long-term studies are required to assess its durability and safety in wider patient populations. Furthermore, combining bulevirtide with existing HBV therapies may offer new avenues for comprehensive management of coinfection.

In terms of prevention, HBV vaccination remains the most effective strategy for reducing HBV and indirectly HDV infection. However, public health strategies must focus on increasing vaccination rates in high-prevalence regions and improving access to antiviral therapies.

While progress has been made in understanding and treating HBV+HDV coinfection, more effective therapies and global efforts are needed to control the spread and impact of these infections. Continued research into HDV-specific treatments, along with improved diagnostic tools, is essential for better patient outcomes.

Conclusion

In conclusion, hepatitis B and D coinfection remains a significant global health challenge, characterized by rapid disease progression and a higher risk of severe liver complications such as cirrhosis and hepatocellular carcinoma. While diagnostic methods for identifying coinfection have improved, treatment options are still limited, with pegylated interferon showing modest success and high relapse rates. The emergence of bulevirtide offers promising potential for targeted HDV therapy, showing encouraging results in early trials. However, long-term efficacy and safety require further study. Prevention through HBV vaccination continues to be the most effective method to reduce the prevalence of HBV and, by extension, HDV infections. Moving forward, a combination of innovative therapies, enhanced public health strategies, and greater access to healthcare in high-prevalence regions is crucial for controlling and mitigating the impact of HBV+HDV coinfection globally. Continued research into HDV-specific treatments and a focus on early diagnosis will be vital to improving patient outcomes and reducing the disease burden.

References

1. Абдурахманов Д.Т., Крель П.Е., Лопаткина Т.Н. и др. Хронический гепатит D: клиническая характеристика, течение и прогноз. Клиническая гепатология 2009;1:47-50.
2. ВОЗ 23 июля 2018 г. [Электронный ресурс]. Режим доступа: https: // www.who.int/ru/news-room/fact-sheets/detail/hepatitis-d/ (дата обращения:17.09.2024).
3. Волкова Н.Н., Ярмухамедова Н.А. Значимость динамики уровня сывороточного маркера фиброза печени WFA+-M2bp у пациентов с хроническим гепатитом В // Журнал гепато-гастроэнтерологических исследований, 2020. Т. 1. № 1.
4. Иноятова Ф. И., Юсупалиева Г. А., Фазылов А. А. Современные технологии эхографии в оценке фиброза печени при хронических вирусных гепатитах у детей // Лучевая диагностика и терапия, 2017. № 3. С. 102-103.
5. Рахимова В.Ш., Эгамова И.Н., Ярмухамедова Н.А. Особенности течения коинфекции ВИЧ и ВГС // Вопросы науки и образования, 2020. №. 22 (106).
6. Ярмухамедова М.К., Ярмухамедова Н.А. Оценка эффективности ПППД у больных с ВГС // Вопросы науки и образования, 2020. № 22 (106).